Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
NCT00816413 · University of Nebraska · PHASE1/PHASE2 · withdrawn · last registry update 2023-08-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Screenings yielded inadequate eligible subjects to enroll.” | – | Registry record, University of Nebraska |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPIA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-24Phase 3 first posted: Shanghai Jiaolian Drug Research and Development Co., Ltd, B007 + Cyclosporin Capsules (NCT06470191)
- 2024-04-30Phase 3 first posted: Université de Sherbrooke, CycloSPORINE Ophthalmic (NCT06392438)
- 2024-04-18Results posted on the registry: Santen SAS, 1mg/mL ciclosporin (NCT03237936)
- 2024-04-05Results posted on the registry: AstraZeneca, Tacrolimus + Cyclosporin (NCT04788641)
- 2024-04-01Results posted on the registry: Merck Sharp & Dohme LLC, Letermovir tablet + Letermovir IV (NCT04129398)
- 2024-03-28Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Letermovir + Valganciclovir (NCT06334497)
- 2024-03-07Also stopped (terminated): King's College London, Biomarker + Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine (NCT02498977)
- 2024-02-06Results posted on the registry: Sun Pharmaceutical Industries Limited, CequaTM (Cyclosporine 0.09%) ophthalmic solution (NCT04357795)
- 2024-02-01Results posted on the registry: Therapeutic Advances in Childhood Leukemia Consortium, Clofarabine + Cyclosporine (NCT01041508)
- 2024-01-30Results posted on the registry: Merck Sharp & Dohme LLC, Letermovir oral granules + Letermovir tablet (NCT03940586)
- 2023-12-18Also stopped (withdrawn): Vishal Jhanji, Cyclosporine + Artificial tear (NCT04515329)
- 2023-12-11Results posted on the registry: Novartis Pharmaceuticals, eltrombopag + Cyclosporine (NCT02998645)
- 2023-12-04Also stopped (terminated): Mario Negri Institute for Pharmacological Research, Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil + Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil (NCT00752479)
- 2023-11-14Results posted on the registry: Ocular Therapeutix, Inc., OTX-CSI (NCT04362670)
- 2023-10-16Results posted on the registry: Novaliq GmbH, CyclASol Ophthalmic Solution (NCT04523142)
- 2023-10-11Results posted on the registry: Thomas Chester, OD, Cyclosporine + Loteprednol Etabonate (NCT04555694)
- 2023-10-10Results posted on the registry: City of Hope Medical Center, busulfan + cyclosporine (NCT00534430)
- 2023-10-03Results posted on the registry: Zambon SpA, Liposomal Cyclosporine A + Liposomal Placebo (NCT04107675)
- 2023-10-03Also stopped (terminated): Zambon SpA, Liposomal Cyclosporine A + Liposomal Placebo (NCT04107675)
- 2023-09-29Also stopped (withdrawn): Amgen, Romiplostim + Antithymocyte Globulin (NCT05323617)
- 2023-09-28Results posted on the registry: Memorial Sloan Kettering Cancer Center, cyclophosphamide + cyclosporine (NCT00574496)
- 2023-09-21Also stopped (withdrawn): Galderma R&D, Nemolizumab + CD14152 placebo (NCT05056779)
- 2023-09-21Also stopped (withdrawn): M.D. Anderson Cancer Center, Fludarabine + Dexamethasone (NCT05293509)
- 2023-08-21Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Maraviroc + Placebo (NCT02741323)
- 2023-08-15Also stopped (terminated): Stanford University, Hematopoietic Cell Transplantation (NCT00325741)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision